The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst
: Thanks very much, and good morning. David, I wanted to start with -- you made some comments around your observations in the
first 100 days. What are some of the things that you think you can really bring to CVS as the new CEO? And anything else that you'd
want to share from an investor perspective, David, as you think of the first 100 days?
And then if I can also just maybe better understand the guidance, which is better than I had anticipated, the guidance being a good
starting point. Tom made the comment of an opportunity for outperformance. Last year, you gave a better-than number. This year,
your range is $5.75 to $6.00. Can you maybe just talk about the confidence in that number and the potential outperformance around
the guidance for 2025? Thanks very much.
Question: Justin Lake - Wolfe Research - Analyst
: Thanks, good morning, I want to follow up on some of your comments there, Tom. First, on your Medicare Advantage trend. Maybe
you can give us a little bit more detail there in terms of what did the trend look like coming out of the year for 2024? And specifically,
what are you assuming for trend in 2025? I know you said it's kind of you're assuming it to keep that pace.
So what the '24 trend and the '25 assumption? And maybe any detail you could share with us on kind of the costs you've taken out
of the business just via the bids, for instance, and how you're seeing your membership mix kind of play out for 2025?
Question: Stephen Baxter - Wells Fargo Securities, LLC - Analyst
: Yeah, hi, thank you. I was hoping you could update us on where the Medicare Advantage margins ended the full year 2024 and
what's assumed in the guidance for 2025. Basically, the pacing of this obviously is going to be a huge area of focus for the investment
community. Any kind of general comments you can talk about progression of MA recovery over the next couple of years beyond
2025 would also be appreciated. Thank you.
Question: Andrew Mok - Barclays - Analyst
: Hi, good morning. We spent a lot of time talking about Medicare margins, but you also took aggressive actions on the individual
ACA business. So I was hoping you could elaborate on those actions, including any changes to provider networks and expected
impact on margins embedded in guidance? Thanks.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
FEBRUARY 12, 2025 / 1:00PM, CVS.N - Q4 2024 CVS Health Corp Earnings Call
Question: Erin Wright - Morgan Stanley - Analyst
: Great, thanks for taking my question. How should we think about the quarterly progression for MLR? And you gave us some of the
detail on your overall assumptions from a utilization perspective for 2025, but any nuances particularly as we model out for the year,
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
FEBRUARY 12, 2025 / 1:00PM, CVS.N - Q4 2024 CVS Health Corp Earnings Call
for instance, how IRA should flow through throughout the year? And any surprises on that front or elements to think about as we
think about that quarterly? Thanks.
Question: Ann Hynes - Mizuho Securities USA - Analyst
: Great, thank you. Can you remind us with CostVantage, what is the headwind to growth the first year of the implementation? And
when would you expect that to turn positive for you? And also, I know CostVantage is only focused on commercial contracts right
now. Do you eventually believe it will impact Medicare contracts? And if so, what's the timing on that? Thanks.
Question: Elizabeth Anderson - Evercore ISI - Analyst
: Hi guys, good morning. Thanks so much for the question. Based on the color on the 2025 outlook in particular, I know you said you
were looking at 4 points of Medicaid improvement year-over-year in terms of the pricing. Can you -- and you said that you had 40%
of it was sort of caught up. Can you talk about how that catches up over the course of 2025? Should we think of that as like broadly
ratable or are there any other kind of considerations to think about for that?
|
